The different pathways to regulatory approval of a biosimilar vary worldwide, ranging from no pathways at all in some developing countries, to the complex and precise mechanism that exists in Europe.
Peter Wittner
Advertisement
Peter Wittner is an independent consultant.
Articles by Peter Wittner
Advertisement
Latest Updated Articles
- Biosimilars: Is It Worth Taking On The Regulators?
Published: August 1st 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
2
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
3
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
4
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
5
